Home › Funds › Ikarian Capital, LLC › OVID
Ikarian Capital, LLC position in OVID
OVID THERAPEUTICS INC · Health Care
Ikarian Capital, LLC reported holding 2,269,704 shares of OVID (OVID THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$6.1M, representing 0.98% of its reported portfolio and ranking #32 among its reported holdings. Ikarian Capital, LLC has disclosed OVID holdings in 4 of the last 4 reported quarters, going back to Q3 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Ikarian Capital, LLC's OVID position evolved
Ikarian Capital, LLC first disclosed a stake in OVID in Q3 2025 at 1,095,574 shares (US$1.4M). The position peaked in Q1 2026 at 2,894,704 shares, worth US$6.4M. Across 4 filings, Ikarian Capital, LLC increased the stake 1 time(s), trimmed it 2 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 2,269,704 shares valued at US$6.1M — a reduction of -625,000 shares quarter over quarter.. Notable position changes include a 77% trim in Q4 2025 (shares rose 36% over the following quarter), a 1069% increase in Q1 2026 (shares rose 21% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2025 | 1.10M | $1.42M | New |
| Q4 2025 | 247.56K | $403.52K | Reduce |
| Q1 2026 | 2.89M | $6.43M | Add |
| Q2 2026 | 2.27M | $6.11M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About OVID and 13F data
OVID (OVID THERAPEUTICS INC) is a Health Care company. 52 other funds we track also report a position in OVID — the largest reported positions include Affinity Asset Advisors, LLC (US$27.3M), ADAR1 Capital Management, LLC (US$20.0M), SILVERARC CAPITAL MANAGEMENT, LLC (US$8.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding OVID
- Affinity Asset Advisors, LLC 10.14M sh · $27.29M · Q2 2026
- ADAR1 Capital Management, LLC 7.42M sh · $19.95M · Q2 2026
- SILVERARC CAPITAL MANAGEMENT, LLC 3.10M sh · $8.34M · Q2 2026
- STEMPOINT CAPITAL LP 2.42M sh · $6.50M · Q2 2026
- Propel Bio Management, LLC 1.12M sh · $3.00M · Q2 2026
- Rosalind Advisors, Inc. 1.11M sh · $2.98M · Q2 2026
- Sio Capital Management, LLC 1.01M sh · $2.70M · Q2 2026
- Saturn V Capital Management LP 663.06K sh · $1.78M · Q2 2026
- Ally Bridge Group (NY) LLC 624.56K sh · $1.68M · Q2 2026
More on Ikarian Capital, LLC
FAQ
How long has Ikarian Capital, LLC held OVID?
Ikarian Capital, LLC has disclosed OVID holdings in 4 of the last 4 reported quarters, going back to Q3 2025.
What is Ikarian Capital, LLC's current position in OVID?
As of Q2 2026, Ikarian Capital, LLC holds 2.27M shares of OVID (OVID THERAPEUTICS INC), valued at $6.11M, representing 0.98% of its reported portfolio and ranking #32.
Has Ikarian Capital, LLC been buying or selling OVID?
In the latest 13F filing (Q2 2026), Ikarian Capital, LLC reduced its position in OVID. The position peaked in Q1 2026 at 2.89M shares.
Which other funds hold OVID?
Other major institutional holders of OVID include Affinity Asset Advisors, LLC, ADAR1 Capital Management, LLC, SILVERARC CAPITAL MANAGEMENT, LLC, among 52 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.